-- Unisplendour (SHE:000938) posted first-quarter attributable net profit of 787.9 million yuan, up 126% from 348.5 million yuan the previous year.
Earnings per share rose to 0.2755 yuan from 0.1219 yuan, according to a Wednesday filing with the Shenzhen bourse.
Operating revenue went up 35% year over year to 28.0 billion yuan from 20.8 billion yuan.
Shares of the semiconductor company were up 1% in recent trade.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:UBS delivered exceptional Q1 2026 results with net profit of USD3.0B (+80% Y/Y) and underlying PBT of USD4.0B (+54% Y/Y), beating consensus estimates. The strong performance reflected broad-based momentum, with underlying revenues advancing 18% and the fourth consecutive quarter of positive operating leverage. UBS achieved a pivotal milestone in the Credit Suisse integration, completing Swiss client account transfers and delivering USD0.8B in additional gross cost savings. Management expressed confidence in substantially completing the integration by year-end 2026 and achieving exit rate targets of an underlying return on CET1 capital of approximately 15% and a cost-to-income ratio below 70%. However, two significant overhangs temper the outlook: proposed Swiss capital framework changes requiring an additional USD22B in CET1 capital represent a material headwind, while elevated geopolitical risks could shift client sentiment given management's guidance for flat net interest income sequentially in Q2 2026.
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:AstraZeneca (AZN) posted 13% total revenue growth (+8% at constant exchange rates, CER) to USD15.3B in Q1 2026, beating consensus estimates of USD14.9B, with oncology remaining the key contributor (+16% CER). Imfinzi climbed 30% CER, supported by multiple new launches, while Enhertu grew 34% CER on continued global demand, with core operating margin remaining broadly stable Y/Y at 35% despite R&D (+8% CER) and SG&A (+7% CER) expense increases. We continue to like AZN for its strong pipeline and numerous key data readouts throughout 2026, supported by four positive Phase 3 trials and 14 regulatory approvals achieved since Q4 2025. AZN reiterated its 2026 guidance for mid- to high-single-digit revenue growth and low double-digit core EPS growth, with currency movements expected to provide modest support. We see this compelling dataset helping support its ambitious target to reach USD80B in total revenue by 2030, with guidance that is more favorable than peers like Novartis.
China Southern Power Grid Energy Storage's (SHA:600995) net profit attributable to shareholders in the first quarter jumped 21% to 453.8 million yuan from almost 374 million yuan a year earlier, according to a Shanghai bourse filing on Wednesday.Earnings per share rose 17% year on year to 0.14 yuan from 0.12 yuan.Operating revenue inched 19% higher to 1.85 billion yuan from 1.56 billion yuan in the previous year.The Chinese state-owned power company's shares closed less than 3% higher.